• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Introduction to 4,8-Dichloro-2-(trifluoromethyl)quinazoline (CAS No. 887592-26-9)

4,8-Dichloro-2-(trifluoromethyl)quinazoline, identified by the Chemical Abstracts Service Number (CAS No.) 887592-26-9, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinazoline class, a scaffold widely recognized for its biological activity and pharmacological potential. The presence of both chloro and trifluoromethyl substituents in its structure imparts unique electronic and steric properties, making it a valuable intermediate in the synthesis of various bioactive molecules.

The quinazoline core is a fused bicyclic system consisting of a benzene ring and a pyridazine ring. This structural motif is known to exhibit a broad spectrum of biological activities, including antiviral, anticancer, antimicrobial, and anti-inflammatory properties. The introduction of electron-withdrawing groups such as chloro and trifluoromethyl further enhances the reactivity and binding affinity of the molecule towards biological targets. Specifically, the 4,8-Dichloro-2-(trifluoromethyl)quinazoline derivative has been explored as a key building block in the development of novel therapeutic agents.

In recent years, there has been an increasing interest in quinazoline derivatives due to their demonstrated efficacy in preclinical studies. One of the most compelling areas of research has been their application in oncology. Quinazoline-based compounds have shown promise as kinase inhibitors, particularly in targeting tyrosine kinases that are overexpressed in cancer cells. The 4,8-Dichloro-2-(trifluoromethyl)quinazoline structure has been investigated for its potential to inhibit enzymes involved in tumor growth and progression. For instance, studies have highlighted its ability to disrupt signaling pathways such as MAPK and PI3K/Akt, which are critical for cancer cell survival and proliferation.

Moreover, the trifluoromethyl group is a well-documented pharmacophore that enhances metabolic stability and binding affinity. Its incorporation into the quinazoline framework increases the lipophilicity of the molecule, facilitating better membrane penetration and target interaction. This feature has been leveraged in designing more potent and selective inhibitors. In contrast, the chloro substituents contribute to the molecule's reactivity by participating in nucleophilic substitution reactions, allowing for further derivatization and optimization.

Recent advancements in computational chemistry have also played a pivotal role in understanding the molecular interactions of 4,8-Dichloro-2-(trifluoromethyl)quinazoline with biological targets. Molecular docking studies have revealed that this compound can bind effectively to ATP-binding pockets of kinases, suggesting its potential as a lead compound for drug development. These computational insights have guided experimental efforts to modify and improve its pharmacological profile.

The synthesis of 4,8-Dichloro-2-(trifluoromethyl)quinazoline involves multi-step organic transformations that require careful optimization to achieve high yields and purity. Common synthetic routes include cyclization reactions followed by halogenation and functional group interconversion. The use of advanced catalytic systems has enabled more efficient synthesis methods, reducing waste generation and improving scalability.

From a medicinal chemistry perspective, the versatility of 4,8-Dichloro-2-(trifluoromethyl)quinazoline as a scaffold allows for diverse structural modifications. Researchers have explored various derivatives by introducing different substituents at strategic positions within the quinazoline ring. These modifications aim to enhance potency, selectivity, solubility, and pharmacokinetic properties. For example, replacing one of the chloro groups with another heterocyclic moiety has led to compounds with improved antitumor activity.

The exploration of 4,8-Dichloro-2-(trifluoromethyl)quinazoline extends beyond oncology into other therapeutic areas such as infectious diseases and inflammation. Preclinical data suggest that certain derivatives exhibit potent activity against viral enzymes like proteases or integrases. Additionally, quinazoline-based molecules have shown promise in modulating inflammatory pathways by inhibiting key cytokines or transcription factors.

In conclusion,4,8-Dichloro-2-(trifluoromethyl)quinazoline (CAS No. 887592-26-9) represents a significant advancement in pharmaceutical research due to its unique structural features and biological potential. Its role as an intermediate in synthesizing novel therapeutic agents underscores its importance in drug discovery efforts aimed at addressing unmet medical needs. As research continues to uncover new applications for this compound,4,8-Dichloro-2-(trifluoromethyl)quinazoline is poised to remain at the forefront of medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)